tacrolimus
Tacrolimus is a lipid of Polyketides (PK) class. Tacrolimus is associated with abnormalities such as Renal glomerular disease. The involved functions are known as inhibitors, Fungicidal activity, Metabolic Inhibition, Excretory function and Dephosphorylation. Tacrolimus often locates in Hepatic, Mitochondrial matrix and Inner mitochondrial membrane. The associated genes with Tacrolimus are RHOA gene and BGN gene.
Cross Reference
Introduction
To understand associated biological information of tacrolimus, we collected biological information of abnormalities, associated pathways, cellular/molecular locations, biological functions, related genes/proteins, lipids and common seen animal/experimental models with organized paragraphs from literatures.
What diseases are associated with tacrolimus?
tacrolimus is suspected in Renal glomerular disease, Candidiasis, Mycoses, PARKINSON DISEASE, LATE-ONSET, Morphologically altered structure, Skin Diseases, Infectious and other diseases in descending order of the highest number of associated sentences.
Related references are mostly published in these journals:
- Antimicrob. Agents Chemother. (2)
- Am. J. Physiol. Renal Physiol. (1)
- Drug Metab. Dispos. (1)
- Others (1)
| Disease | Cross reference | Weighted score | Related literature |
|---|
Loading... please refresh the page if content is not showing up.
Possible diseases from mapped MeSH terms on references
We collected disease MeSH terms mapped to the references associated with tacrolimus
PubChem Associated disorders and diseases
What pathways are associated with tacrolimus
There are no associated biomedical information in the current reference collection.
PubChem Biomolecular Interactions and Pathways
Link to PubChem Biomolecular Interactions and PathwaysWhat cellular locations are associated with tacrolimus?
Visualization in cellular structure
Associated locations are in red color. Not associated locations are in black.
Related references are published most in these journals:
| Location | Cross reference | Weighted score | Related literatures |
|---|
Loading... please refresh the page if content is not showing up.
What functions are associated with tacrolimus?
Related references are published most in these journals:
| Function | Cross reference | Weighted score | Related literatures |
|---|
What lipids are associated with tacrolimus?
Related references are published most in these journals:
| Lipid concept | Cross reference | Weighted score | Related literatures |
|---|
Loading... please refresh the page if content is not showing up.
What genes are associated with tacrolimus?
Related references are published most in these journals:
| Gene | Cross reference | Weighted score | Related literatures |
|---|
What common seen animal models are associated with tacrolimus?
There are no associated biomedical information in the current reference collection.
NCBI Entrez Crosslinks
All references with tacrolimus
Download all related citations| Authors | Title | Published | Journal | PubMed Link |
|---|---|---|---|---|
| Schnitzler M | Diabetes mellitus after kidney transplantation in the United States. | 2003 | Am. J. Transplant. | pmid:14510709 |
| Spada M et al. | Randomized trial of basiliximab induction versus steroid therapy in pediatric liver allograft recipients under tacrolimus immunosuppression. | 2006 | Am. J. Transplant. | pmid:16771811 |
| Donners MM et al. | Low-dose FK506 blocks collar-induced atherosclerotic plaque development and stabilizes plaques in ApoE-/- mice. | 2005 | Am. J. Transplant. | pmid:15888024 |
| Woodward RS et al. | Incidence and cost of new onset diabetes mellitus among U.S. wait-listed and transplanted renal allograft recipients. | 2003 | Am. J. Transplant. | pmid:12752315 |
| Lehmann R et al. | Successful simultaneous islet-kidney transplantation using a steroid-free immunosuppression: two-year follow-up. | 2004 | Am. J. Transplant. | pmid:15196070 |
| Lemahieu W et al. | Cytochrome P450 3A4 and P-glycoprotein activity and assimilation of tacrolimus in transplant patients with persistent diarrhea. | 2005 | Am. J. Transplant. | pmid:15888045 |
| Axelrod D et al. | Reduction of CMV disease with steroid-free immunosuppresssion in simultaneous pancreas-kidney transplant recipients. | 2005 | Am. J. Transplant. | pmid:15888050 |
| Kim EJ et al. | Costimulation blockade alters germinal center responses and prevents antibody-mediated rejection. | 2014 | Am. J. Transplant. | pmid:24354871 |
| Frassetto LA et al. | Immunosuppressant pharmacokinetics and dosing modifications in HIV-1 infected liver and kidney transplant recipients. | 2007 | Am. J. Transplant. | pmid:17949460 |
| Campbell PM et al. | Pretransplant HLA antibodies are associated with reduced graft survival after clinical islet transplantation. | 2007 | Am. J. Transplant. | pmid:17456201 |
| Singh K et al. | Superiority of rapamycin over tacrolimus in preserving nonhuman primate Treg half-life and phenotype after adoptive transfer. | 2014 | Am. J. Transplant. | pmid:25359003 |
| Dugast E et al. | Failure of Calcineurin Inhibitor (Tacrolimus) Weaning Randomized Trial in Long-Term Stable Kidney Transplant Recipients. | 2016 | Am. J. Transplant. | pmid:27367750 |
| Tang Q | Pharmacokinetics of therapeutic Tregs. | 2014 | Am. J. Transplant. | pmid:25358900 |
| Wen X et al. | Comparison of Utilization and Clinical Outcomes for Belatacept- and Tacrolimus-Based Immunosuppression in Renal Transplant Recipients. | 2016 | Am. J. Transplant. | pmid:27137884 |
| Trofe-Clark J et al. | Immunosuppression, generic drugs and the FDA. | 2012 | Am. J. Transplant. | pmid:22176626 |
| Sikma MA et al. | Pharmacokinetics and Toxicity of Tacrolimus Early After Heart and Lung Transplantation. | 2015 | Am. J. Transplant. | pmid:26053114 |
| Latran M | Response to Klintmalm on the use of generic immunosuppression. | 2012 | Am. J. Transplant. | pmid:22176636 |
| English RF et al. | Long-term comparison of tacrolimus- and cyclosporine-induced nephrotoxicity in pediatric heart-transplant recipients. | 2002 | Am. J. Transplant. | pmid:12243498 |
| de Fontbrune FS et al. | Veno-occlusive disease of the liver after lung transplantation. | 2007 | Am. J. Transplant. | pmid:17697264 |
| Kurtz J et al. | Lack of role for CsA-sensitive or Fas pathways in the tolerization of CD4 T cells via BMT and anti-CD40L. | 2003 | Am. J. Transplant. | pmid:12814472 |
| Gupta G et al. | Safe Conversion From Tacrolimus to Belatacept in High Immunologic Risk Kidney Transplant Recipients With Allograft Dysfunction. | 2015 | Am. J. Transplant. | pmid:25988397 |
| Ekberg H et al. | Calcineurin inhibitor minimization in the Symphony study: observational results 3 years after transplantation. | 2009 | Am. J. Transplant. | pmid:19563339 |
| Mehra MR et al. | Immunosuppression in cardiac transplantation: science, common sense and the heart of the matter. | 2006 | Am. J. Transplant. | pmid:16686745 |
| Grimm M et al. | Superior prevention of acute rejection by tacrolimus vs. cyclosporine in heart transplant recipients--a large European trial. | 2006 | Am. J. Transplant. | pmid:16686762 |
| Sis B et al. | Reproducibility studies on arteriolar hyaline thickening scoring in calcineurin inhibitor-treated renal allograft recipients. | 2006 | Am. J. Transplant. | pmid:16686769 |
| Damon C et al. | Predictive Modeling of Tacrolimus Dose Requirement Based on High-Throughput Genetic Screening. | 2017 | Am. J. Transplant. | pmid:27597269 |
| Shuker N et al. | A Randomized Controlled Trial Comparing the Efficacy of Cyp3a5 Genotype-Based With Body-Weight-Based Tacrolimus Dosing After Living Donor Kidney Transplantation. | 2016 | Am. J. Transplant. | pmid:26714287 |
| Bouamar R et al. | Tacrolimus predose concentrations do not predict the risk of acute rejection after renal transplantation: a pooled analysis from three randomized-controlled clinical trials(†). | 2013 | Am. J. Transplant. | pmid:23480233 |
| Busque S et al. | The PROMISE study: a phase 2b multicenter study of voclosporin (ISA247) versus tacrolimus in de novo kidney transplantation. | 2011 | Am. J. Transplant. | pmid:21943027 |
| Hamdy AF et al. | Comparison of sirolimus with low-dose tacrolimus versus sirolimus-based calcineurin inhibitor-free regimen in live donor renal transplantation. | 2005 | Am. J. Transplant. | pmid:16162204 |
| Kaufman DB et al. | Alemtuzumab induction and prednisone-free maintenance immunotherapy in kidney transplantation: comparison with basiliximab induction--long-term results. | 2005 | Am. J. Transplant. | pmid:16162205 |
| Schwarz A et al. | Polyoma virus nephropathy in native kidneys after lung transplantation. | 2005 | Am. J. Transplant. | pmid:16162212 |
| Flechner SM et al. | Allotransplantation of cryopreserved parathyroid tissue for severe hypocalcemia in a renal transplant recipient. | 2010 | Am. J. Transplant. | pmid:20883540 |
| BenÃtez CE et al. | ATG-Fresenius treatment and low-dose tacrolimus: results of a randomized controlled trial in liver transplantation. | 2010 | Am. J. Transplant. | pmid:20883560 |
| Böger CA et al. | Reverse diastolic intrarenal flow due to calcineurin inhibitor (CNI) toxicity. | 2006 | Am. J. Transplant. | pmid:16889550 |
| Shemesh E et al. | The Medication Level Variability Index (MLVI) Predicts Poor Liver Transplant Outcomes: A Prospective Multi-Site Study. | 2017 | Am. J. Transplant. | pmid:28321975 |
| Tan HP et al. | Living donor renal transplantation using alemtuzumab induction and tacrolimus monotherapy. | 2006 | Am. J. Transplant. | pmid:16889606 |
| Hirsch HH et al. | BK Polyomavirus Replication in Renal Tubular Epithelial Cells Is Inhibited by Sirolimus, but Activated by Tacrolimus Through a Pathway Involving FKBP-12. | 2016 | Am. J. Transplant. | pmid:26639422 |
| Pescovitz MD et al. | A randomized, double-blind, pharmacokinetic study of oral maribavir with tacrolimus in stable renal transplant recipients. | 2009 | Am. J. Transplant. | pmid:19663892 |
| Bohl DL et al. | Donor origin of BK virus in renal transplantation and role of HLA C7 in susceptibility to sustained BK viremia. | 2005 | Am. J. Transplant. | pmid:16095500 |
| Kasahara M et al. | Living-donor liver transplantation for hepatoblastoma. | 2005 | Am. J. Transplant. | pmid:16095502 |
| Lemahieu WP et al. | Combined therapy with atorvastatin and calcineurin inhibitors: no interactions with tacrolimus. | 2005 | Am. J. Transplant. | pmid:16095503 |
| Meier-Kriesche HU et al. | Sirolimus in combination with tacrolimus is associated with worse renal allograft survival compared to mycophenolate mofetil combined with tacrolimus. | 2005 | Am. J. Transplant. | pmid:16095509 |
| Senior PA et al. | Proteinuria developing after clinical islet transplantation resolves with sirolimus withdrawal and increased tacrolimus dosing. | 2005 | Am. J. Transplant. | pmid:16095517 |
| Gao R et al. | Effects of immunosuppressive drugs on in vitro neogenesis of human islets: mycophenolate mofetil inhibits the proliferation of ductal cells. | 2007 | Am. J. Transplant. | pmid:17391142 |
| Meier-Kriesche HU and Kaplan B | Cyclosporine microemulsion and tacrolimus are associated with decreased chronic allograft failure and improved long-term graft survival as compared with sandimmune. | 2002 | Am. J. Transplant. | pmid:12095048 |
| Rodriguez-Rodriguez AE et al. | The higher diabetogenic risk of tacrolimus depends on pre-existing insulin resistance. A study in obese and lean Zucker rats. | 2013 | Am. J. Transplant. | pmid:23651473 |
| Tremblay S et al. | A Steady-State Head-to-Head Pharmacokinetic Comparison of All FK-506 (Tacrolimus) Formulations (ASTCOFF): An Open-Label, Prospective, Randomized, Two-Arm, Three-Period Crossover Study. | 2017 | Am. J. Transplant. | pmid:27340950 |
| Padiyar A et al. | Clinical predictors of proteinuria after conversion to sirolimus in kidney transplant recipients. | 2010 | Am. J. Transplant. | pmid:20055793 |
| Hardinger KL et al. | BK-virus and the impact of pre-emptive immunosuppression reduction: 5-year results. | 2010 | Am. J. Transplant. | pmid:20055811 |
| Neuberger JM et al. | Delayed introduction of reduced-dose tacrolimus, and renal function in liver transplantation: the 'ReSpECT' study. | 2009 | Am. J. Transplant. | pmid:19120077 |
| Momper JD et al. | The impact of conversion from prograf to generic tacrolimus in liver and kidney transplant recipients with stable graft function. | 2011 | Am. J. Transplant. | pmid:21714845 |
| Tan HP et al. | Two hundred living donor kidney transplantations under alemtuzumab induction and tacrolimus monotherapy: 3-year follow-up. | 2009 | Am. J. Transplant. | pmid:19120078 |
| Ashman N et al. | Belatacept as maintenance immunosuppression for postrenal transplant de novo drug-induced thrombotic microangiopathy. | 2009 | Am. J. Transplant. | pmid:19120084 |
| Lemahieu WP et al. | CYP3A4 and P-glycoprotein activity in healthy controls and transplant patients on cyclosporin vs. tacrolimus vs. sirolimus. | 2004 | Am. J. Transplant. | pmid:15307840 |
| Vongwiwatana A et al. | Peritubular capillary changes and C4d deposits are associated with transplant glomerulopathy but not IgA nephropathy. | 2004 | Am. J. Transplant. | pmid:14678043 |
| Bressollette-Bodin C et al. | A prospective longitudinal study of BK virus infection in 104 renal transplant recipients. | 2005 | Am. J. Transplant. | pmid:15996241 |
| Augustine JJ et al. | Pre-transplant IFN-gamma ELISPOTs are associated with post-transplant renal function in African American renal transplant recipients. | 2005 | Am. J. Transplant. | pmid:15996247 |
| Filler G et al. | Adding sirolimus to tacrolimus-based immunosuppression in pediatric renal transplant recipients reduces tacrolimus exposure. | 2005 | Am. J. Transplant. | pmid:15996252 |
| Fan DM et al. | Successful ABO-incompatible living-related intestinal transplantation: a 2-year follow-up. | 2015 | Am. J. Transplant. | pmid:25808777 |
| Awadalla Y et al. | HLA mismatching increases the risk of BK virus nephropathy in renal transplant recipients. | 2004 | Am. J. Transplant. | pmid:15367226 |
| Froud T et al. | Islet transplantation in type 1 diabetes mellitus using cultured islets and steroid-free immunosuppression: Miami experience. | 2005 | Am. J. Transplant. | pmid:15996257 |
| Borrows R et al. | Mycophenolic acid 12-h trough level monitoring in renal transplantation: association with acute rejection and toxicity. | 2006 | Am. J. Transplant. | pmid:16433766 |
| Luther P and Baldwin D | Pioglitazone in the management of diabetes mellitus after transplantation. | 2004 | Am. J. Transplant. | pmid:15575920 |
| Dahm F et al. | Conversion from cyclosporine to tacrolimus improves quality-of-life indices, renal graft function and cardiovascular risk profile. | 2004 | Am. J. Transplant. | pmid:15575921 |
| Pascher A et al. | Protein kinase C inhibitor sotrastaurin in de novo liver transplant recipients: a randomized phase II trial. | 2015 | Am. J. Transplant. | pmid:25677074 |
| Okabayashi T et al. | Mobilization of host stem cells enables long-term liver transplant acceptance in a strongly rejecting rat strain combination. | 2011 | Am. J. Transplant. | pmid:21883903 |
| Hellemons ME et al. | Former smoking is a risk factor for chronic kidney disease after lung transplantation. | 2011 | Am. J. Transplant. | pmid:21883906 |
| Mulay AV et al. | Impact of immunosuppressive medication on the risk of renal allograft failure due to recurrent glomerulonephritis. | 2009 | Am. J. Transplant. | pmid:19353768 |
| Bourdeaux C et al. | Living-related versus deceased donor pediatric liver transplantation: a multivariate analysis of technical and immunological complications in 235 recipients. | 2007 | Am. J. Transplant. | pmid:17173657 |
| Zheng H et al. | Tacrolimus dosing in pediatric heart transplant patients is related to CYP3A5 and MDR1 gene polymorphisms. | 2003 | Am. J. Transplant. | pmid:12694072 |
| Montgomery SP et al. | Efficacy and toxicity of a protocol using sirolimus, tacrolimus and daclizumab in a nonhuman primate renal allotransplant model. | 2002 | Am. J. Transplant. | pmid:12118862 |
| Ahsan N et al. | Limited dose monoclonal IL-2R antibody induction protocol after primary kidney transplantation. | 2002 | Am. J. Transplant. | pmid:12118902 |
| Rostaing L et al. | Alefacept combined with tacrolimus, mycophenolate mofetil and steroids in de novo kidney transplantation: a randomized controlled trial. | 2013 | Am. J. Transplant. | pmid:23730730 |
| van Hooff JP et al. | Glucose metabolic disorder after transplantation. | 2007 | Am. J. Transplant. | pmid:17511670 |
| Heffron TG et al. | Once-daily tacrolimus extended-release formulation: 1-year post-conversion in stable pediatric liver transplant recipients. | 2007 | Am. J. Transplant. | pmid:17511684 |
| Moench C et al. | Tacrolimus monotherapy without steroids after liver transplantation--a prospective randomized double-blinded placebo-controlled trial. | 2007 | Am. J. Transplant. | pmid:17511685 |
| Patlolla V et al. | Efficacy of anti-IL-2 receptor antibodies compared to no induction and to antilymphocyte antibodies in renal transplantation. | 2007 | Am. J. Transplant. | pmid:17564638 |
| Min SI et al. | Conversion of twice-daily tacrolimus to once-daily tacrolimus formulation in stable pediatric kidney transplant recipients: pharmacokinetics and efficacy. | 2013 | Am. J. Transplant. | pmid:23734831 |
| Tedesco-Silva H et al. | Reduced Incidence of Cytomegalovirus Infection in Kidney Transplant Recipients Receiving Everolimus and Reduced Tacrolimus Doses. | 2015 | Am. J. Transplant. | pmid:25988935 |
| McDonald RA et al. | Incidence of PTLD in pediatric renal transplant recipients receiving basiliximab, calcineurin inhibitor, sirolimus and steroids. | 2008 | Am. J. Transplant. | pmid:18416737 |
| Vanhove T et al. | High Intrapatient Variability of Tacrolimus Concentrations Predicts Accelerated Progression of Chronic Histologic Lesions in Renal Recipients. | 2016 | Am. J. Transplant. | pmid:27013142 |
| Posselt AM et al. | Islet transplantation in type 1 diabetics using an immunosuppressive protocol based on the anti-LFA-1 antibody efalizumab. | 2010 | Am. J. Transplant. | pmid:20659093 |
| Pradhan M et al. | Decline in renal function following thoracic organ transplantation in children. | 2002 | Am. J. Transplant. | pmid:12201367 |
| Teuteberg JJ et al. | Alemtuzumab induction prior to cardiac transplantation with lower intensity maintenance immunosuppression: one-year outcomes. | 2010 | Am. J. Transplant. | pmid:19889126 |
| Jacobson PA et al. | Lower calcineurin inhibitor doses in older compared to younger kidney transplant recipients yield similar troughs. | 2012 | Am. J. Transplant. | pmid:22947444 |
| Shapiro R et al. | Alemtuzumab pre-conditioning with tacrolimus monotherapy in pediatric renal transplantation. | 2007 | Am. J. Transplant. | pmid:17908272 |
| De Simone P et al. | Everolimus with reduced tacrolimus improves renal function in de novo liver transplant recipients: a randomized controlled trial. | 2012 | Am. J. Transplant. | pmid:22882750 |
| Echeverri GJ et al. | Endoscopic gastric submucosal transplantation of islets (ENDO-STI): technique and initial results in diabetic pigs. | 2009 | Am. J. Transplant. | pmid:19775318 |
| Gaston RS et al. | Fixed- or controlled-dose mycophenolate mofetil with standard- or reduced-dose calcineurin inhibitors: the Opticept trial. | 2009 | Am. J. Transplant. | pmid:19459794 |
| Rush D et al. | Lack of benefit of early protocol biopsies in renal transplant patients receiving TAC and MMF: a randomized study. | 2007 | Am. J. Transplant. | pmid:17908280 |
| Turgut F and Akcay A | Renal function estimation in cirrhosis. | 2009 | Am. J. Transplant. | pmid:19519814 |
| Irish WD et al. | Cyclosporine versus tacrolimus treated liver transplant recipients with chronic hepatitis C: outcomes analysis of the UNOS/OPTN database. | 2011 | Am. J. Transplant. | pmid:21564522 |
| Tricot L et al. | Safety and efficacy of raltegravir in HIV-infected transplant patients cotreated with immunosuppressive drugs. | 2009 | Am. J. Transplant. | pmid:19519819 |
| Friman S et al. | Sotrastaurin, a novel small molecule inhibiting protein-kinase C: randomized phase II study in renal transplant recipients. | 2011 | Am. J. Transplant. | pmid:21564523 |
| Kofler S et al. | Proton pump inhibitors reduce mycophenolate exposure in heart transplant recipients-a prospective case-controlled study. | 2009 | Am. J. Transplant. | pmid:19519820 |
| Gatault P et al. | Reduction of Extended-Release Tacrolimus Dose in Low-Immunological-Risk Kidney Transplant Recipients Increases Risk of Rejection and Appearance of Donor-Specific Antibodies: A Randomized Study. | 2017 | Am. J. Transplant. | pmid:27862923 |
| Margreiter R et al. | Alemtuzumab (Campath-1H) and tacrolimus monotherapy after renal transplantation: results of a prospective randomized trial. | 2008 | Am. J. Transplant. | pmid:18510632 |
| Brennan DC et al. | Incidence of BK with tacrolimus versus cyclosporine and impact of preemptive immunosuppression reduction. | 2005 | Am. J. Transplant. | pmid:15707414 |
| Rogers J et al. | Effect of ethnicity on outcome of simultaneous pancreas and kidney transplantation. | 2003 | Am. J. Transplant. | pmid:14510702 |